Buscar resultados de ensayos clínicos
Leukemia, Myelomonocytic, Acute - 25 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML Condición: Leukemia, Myelomonocytic, Acute Fecha: 2006-08-10 Intervenciones: Drug: XIAP antisense 2 days loading dose followed by weekly 2hr infusion |
Completed |
Nombre del estudio: Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia Condición: Leukemia, Myelomonocytic, Acute Fecha: 2010-07-30 Intervenciones: Drug: Erlotinib Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle wil |
Withdrawn |
Nombre del estudio: A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia Condición:
|
Completed |
Nombre del estudio: Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia Condición:
Intervenciones: Other: laboratory biomarker analysis Correlative studies |
Recruiting |
Nombre del estudio: A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) Condición: Leukemia, Myelomonocytic, Chronic Fecha: 2017-01-24 Intervenciones:
|
Recruiting |
Nombre del estudio: Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia Condición: Leukemia, Myelomonocytic, Chronic Fecha: 2016-06-15 Intervenciones: Drug: Tipifarnib Oral tablet Other Names: |
Recruiting |
Nombre del estudio: Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) Condición: Chronic Myelomonocytic Leukemia (CMML) Fecha: 2015-08-27 Intervenciones: Drug: lenzilumab Other Names:
|
Active, not recruiting |
Nombre del estudio: A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib Condición: Myelomonocytic Leukemia Fecha: 2013-01-24 Intervenciones: Drug: Ruxolitinib In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to |
Active, not recruiting |
Nombre del estudio: Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Condición: Chronic Myelomonocytic Leukemia Fecha: 2011-05-09 Intervenciones: Drug: Revlimid Dose escalation 5mg - 10mg - 15mg - 20mg in |
Completed |
Nombre del estudio: A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia Condición: Chronic Myelomonocytic Leukemia Fecha: 2011-04-29 Intervenciones: Drug: 5-Azacitidine Administered on Days 1-7 of each Cycle |